UE LifeSciences Inc. Announces FDA Clearance for Complementary Breast Cancer Screening Device

The Associated Press

PHILADELPHIA--(BUSINESS WIRE)--Mar 5, 2012-- UE LifeSciences Inc.

(UELS), a medical device manufacturer focused on providing novel breast cancer screening solutions, announced today that it has received market clearance from the U.S. Food and Drug Administration (FDA) for its NoTouch BreastScan(TM) device. NoTouch BreastScan(TM) is a contactless breast-imaging tool cleared by the FDA specifically for adjunctive diagnostic screening for the detection of breast cancer.

NoTouch BreastScan(TM) is the first fully computerized functional infrared imaging system that incorporates patent pending dual-infrared detector design. Unlike most breast thermography solutions, NoTouch BreastScan(TM) does not require manual interpretation of thermal data; instead, it dynamically analyzes temperature pixels from various infrared frames to create a real-time objective report for the doctor.

"We are pleased with FDA's decision to finally bring NoTouch to the US market," Matthew Campisi, VP Technology commented. "This computerized technology truly complements conventional tools, albeit without the pain and radiation aspects," he added.

"NoTouch BreastScan(TM) does not discriminate dense breast tissue, which is good news for tens of millions of women in America," said Azad Anand, MD, Radiologist and Director, Long Island Diagnostic Imaging in New York. John Gomes, MD, a leading gynecologist in New York says, "It looks at breast cancer from a physiologic vantage point not visible to anatomic imaging modalities like mammography and ultrasound. So when we combine the information from both sides, we can assess the full picture." UE LifeSciences Inc. plans to offer NoTouch BreastScan(TM) services to Gynecology, Medical Oncology and Radiology clinics in the U.S.

starting from New York, New Jersey and Pennsylvania regions.

About UE LifeSciences Inc.

UE LifeSciences Inc. (UELS) is a Philadelphia, PA based corporation with a mission to design, develop and commercialize globally adoptable and clinically effective non-invasive breast cancer detection solutions for women of all ages and demographics. UELS creates automated technologies that do not require highly skilled medical practitioners for accurate test administration and data analysis. In addition to NoTouch BreastScan(TM), UELS is developing iBE(TM) (Intelligent Breast Exam), a patented hand-held tactile sensor technology for early stage breast cancer detection.

CONTACT: UE LifeSciences Inc.

Bakulesh Shah, +1 631-980-8340 Info@NoTouchBreastScan.com http://www.NoTouchBreastScan.com KEYWORD: UNITED STATES NORTH AMERICA PENNSYLVANIA INDUSTRY KEYWORD: WOMEN TECHNOLOGY OTHER TECHNOLOGY HEALTH MEDICAL DEVICES ONCOLOGY FDA CONSUMER GENERAL HEALTH SOURCE: UE LifeSciences Inc.

Copyright Business Wire 2012 PUB: 03/05/2012 09:00 AM/DISC: 03/05/2012 09:00 AM http://www.businesswire.com/news/home/20120305005252/

Source URL (retrieved on *03/27/2015 - 12:27am*):
http://www.mdtmag.com/news/2012/03/ue-lifesciences-inc-announces-fda-clearance-complementary-breast-cancer-screening-device